Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic
Abstract
:1. Introduction
2. Methods and Theoretical Foundations
Transaction Cost # Reduction Element | Planning Tool |
---|---|
1. Government mandate | Ambiguity analysis |
2. Use of established networks | Complexity analysis |
3. Fast onboarding and securing of commitment | Stakeholder [28,29] and possible failure analysis |
4. Informed planning of supply capacity | Volatility and uncertainty analysis |
5. Secure availability of critical items | Risk management analysis [30] |
3. Transaction Cost-Reduction Measure 1–Government Support
3.1. Planning Tool: Ambiguity Analysis
3.2. Mitigation Strategy for Ambiguity: Agility, Based on a Clear Mission
4. Transaction Cost-Reduction Measure 2–Use of Established Networks
4.1. Planning Tool: Complexity Analysis
4.2. Mitigation Strategy for Complexity: Clarity and Concentration by Integrating All Relevant Partners in a Task Force
5. Transaction Cost-Reduction Measure 3–Fast Onboarding of Project Partners and Securing Their Commitment
5.1. Planning Tool 3a: Stakeholder Analysis and Management
5.2. Planning Tool 3b: Possible Failure Analysis
6. Transaction Cost-Reduction Measure 4–Informed Planning of Supply Capacities
6.1. Planning Tool 4a: Volatility Analysis
Mitigation Strategy for Volatility: Vision
6.2. Planning Tool 4b: Uncertainty Analysis
Mitigation Strategy for Uncertainty: Understanding
7. Transaction Cost-Reduction Measure 5–Secure Availabilities of Strategic, Specific, and Uncertainty-Subjected Contributions
7.1. Planning Tool: Risk Management Analysis
7.1.1. Misalignment of Players
7.1.2. Scheduling Issues
7.1.3. Logistic Issues
7.1.4. Terror and Manipulation
7.1.5. Ineffectiveness of Vaccines
7.1.6. Mission Cancelled
7.1.7. Vaccine Safety Signals
7.1.8. IT Issues
8. Limitations
9. Lessons Learned and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Available online: https://coronavirus.jhu.edu/map.html (accessed on 14 April 2021).
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- European Medicines Agency. EMA Recommends First COVID-19 Vaccine for Authorisation in the EU. Available online: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu (accessed on 16 April 2021).
- Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef] [PubMed]
- Voysey, M.; Clemens, S.A.C.; Madhi, S.A.; Weckx, L.Y.; Folegatti, P.M.; Aley, P.K.; Angus, B.; Baillie, V.L.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021, 397, 99–111. [Google Scholar] [CrossRef]
- Sadoff, J.; Gray, G.; Vandebosch, A.; Cardenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.; Fennema, H.; Spiessens, B.; et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N. Engl. J. Med. 2021, 384, 2187–2201. [Google Scholar] [CrossRef] [PubMed]
- Robert Koch Institut. Nationale Impfstrategie COVID-19. Available online: https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/COVID-19/Impfstrategie_Covid19.pdf?__blob=publicationFile (accessed on 16 April 2021).
- Williamsson, O.E. The Economic Institutions of Capitalism: Firms, Markets, Relational Contracting; The Free Press: New York, NY, USA, 1985. [Google Scholar]
- Coase, R.H. The Nature of the Firm. Economia 1937, 4, 386–404. [Google Scholar]
- Williamsson, O.E. Transaction Cost Economics: The Natural Progression. Am. Econ. Rev. 2010, 100, 673–690. [Google Scholar] [CrossRef] [Green Version]
- Creswell, J.W. Narrative Research. In Qualitative Inquiry & Research Design: Choosing Among Five Approaches; Sage: Washington, DC, USA, 2012; pp. 70–76. [Google Scholar]
- Creswell, J.W. Phenomenological Research. In Qualitative Inquiry & Research Design: Choosing Among Five Approaches; Sage: Washington, DC, USA, 2012; pp. 76–83. [Google Scholar]
- Partners in Health. Our approach—PIH’s "Five S’s". Available online: https://www.pih.org/our-approach (accessed on 29 July 2021).
- Mink, O.G.; Esterhuysen, P.W.; Monk, B.P.; Owen, K.Q. A Comprehensive Management Process. for Transforming Organizations; Jossey-Bass Publishers: San Franscisco, CA, USA, 1993; pp. 440–441. [Google Scholar]
- Baran, B.E.; Woznyj, H.M. Managing VUCA: The human dynamics of agility. Organ. Dyn 2020, 16, 100787. [Google Scholar] [CrossRef]
- Casey, G.W., Jr. Leading in a ’VUCA’ world. Fortune 2014, 169, 75–76. [Google Scholar] [PubMed]
- Bennett, N.; Lemoine, G.J. What a difference a word makes: Understanding threats to performance in a VUCA world. Bus. Horiz. 2014, 57, 311–317. [Google Scholar] [CrossRef]
- Nicholson, P.J. Health risk from job insecurity needs to be mitigated in these "VUCA times". BMJ 2013, 347, f5504. [Google Scholar] [CrossRef]
- Till, A.; Dutta, N.; McKimm, J. Vertical leadership in highly complex and unpredictable health systems. Br. J. Hosp. Med. 2016, 77, 471–475. [Google Scholar] [CrossRef] [PubMed]
- Alkhaldi, K.H.; Austin, M.L.; Cura, B.A.; Dantzler, D.; Holland, L.; Maples, D.L.; Quarrelles, J.C.; Weinkle, R.K., Jr.; Marcus, L.J. Are you ready? Crisis leadership in a hyper-VUCA environment. Am. J. Disaster Med. 2017, 12, 107–134. [Google Scholar] [CrossRef]
- Maini, A.; Saravanan, Y.; Singh, T.A.; Fyfe, M. Coaching skills for medical education in a VUCA world. Med. Teach. 2020, 42, 1308–1309. [Google Scholar] [CrossRef] [PubMed]
- Onaca, N.; Fleshman, J.W. Types of Leadership and How to Use Them in Surgical Areas. Clin. Colon. Rectal. Surg. 2020, 33, 228–232. [Google Scholar] [CrossRef] [PubMed]
- Thomas, C. Decision-making during VUCA crises: Insights from the 2017 Northern California firestorm. J. Bus. Contin. Emer. Plan. 2020, 14, 82–94. [Google Scholar]
- Garcia-Lopez, J.; Delgadillo, J.; Vilarrodona, A.; Querol, S.; Ovejo, J.; Coll, R.; Millan, A.; Madrigal, A.; Soria, G.; Vidal, F.; et al. SARS-CoV-2/COVID-19 pandemic: First wave, impact, response and lessons learnt in a fully integrated Regional Blood and Tissue Bank. A narrative report. Blood Transfus 2021, 19, 158–167. [Google Scholar] [CrossRef]
- Sturmberg, J.P. Without Systems and Complexity Thinking There Is no Progress or Why Bureaucracy Needs to Become Curious Comment on "What Can Policy-Makers Get out of Systems Thinking? Policy Partners’ Experiences of a Systems-Focused Research Collaboration in Preventive Health". Int. J. Health Policy Manag. 2021, 10, 277–280. [Google Scholar] [CrossRef]
- Yoder-Wise, P.S. From VUCA to VUCA 2.0: Surviving Today to Prosper Tomorrow. Nurs. Educ. Perspect 2021, 42, 1–2. [Google Scholar] [CrossRef]
- Ries, M.; Mechler, K.; Smith, D.L.; Herfort, B.; Visintini, J.; Santana, A.V.; Zipf, A.; Lautenbach, S. Intuitive Global Insight Into COVID-19 Clinical Research Activities-The "COVID-19 Map of Hope". J. Clin. Pharmacol. 2020, 60, 826–827. [Google Scholar] [CrossRef]
- Varvasovszky, Z.; Brugha, R. A stakeholder analysis. Health Policy Plan. 2000, 15, 338–345. [Google Scholar] [CrossRef]
- Donaldson, T.; Preston, L. The stakeholder theory of the corporation: Concepts, evidence, and implications. Acad. Manag. Rev. 1995, 20, 65–91. [Google Scholar] [CrossRef] [Green Version]
- Olofsson, A.; Zinn, J.O. Researching Risk and Uncertainty: Methodologies, Methods and Research Strategies; Springer: Berlin/Heidelberg, Germany, 2019. [Google Scholar]
- Ries, M.; Zielonka, M.; Ries, N.; Breil, T.; Garbade, S.; Mechler, K. Disasters in Germany and France: An Analysis of the Emergency Events Database From a Pediatric Perspective. Disaster Med. Public Health Prep. 2019, 13, 958–965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brennenstuhl, H.; Will, M.; Ries, E.; Mechler, K.; Garbade, S.; Ries, M. Patterns of extreme temperature-related catastrophic events in Europe including the Russian Federation: A cross-sectional analysis of the Emergency Events Database. BMJ Open 2021, 11, e046359. [Google Scholar] [CrossRef] [PubMed]
- Levey, J.; Levey, M. Mindful leadership for personal and organisational resilience. Clin. Radiol. 2019, 74, 739–745. [Google Scholar] [CrossRef] [PubMed]
Top 10 Priorities | 10 Major Pitfalls |
---|---|
1. Create a task force with all relevant partners so all information can be shared, also create smaller expert groups | 1. Change standard operation procedures frequently |
2. Involve actual end-users of the centers in the planning phase | 2. Set unrealistic goals |
3. Start giving information to the operators of the vaccination centers as fast as possible, through clear and easy means of communication | 3. Open vaccination centers prematurely |
4. Start an early information campaign towards the general public to keep everyone involved | 4. Start acting before core planning is finalized |
5. Listen to the staff members and respect users | 5. Open too many vaccination centers at once in the starting phase if vaccine supply is limited |
6. Have a functioning system and appropriate standard operation procedures that can change in response to lessons learned | 6. Delay the second step of the rollout phase, i.e., shifting vaccinations from center to doctors’ offices |
7. Adapt quickly to new situations | 7. Create a whole new system instead of involving and building on already existing structures |
8. Have common standards that apply to vaccination centers in the whole country to avoid “vaccination tourism“ | 8. Work with the cheapest contractor without considering how experienced that contractor is |
9. Set aside any prior conflicts with organizations or institutions, work together as a team for the best results possible | 9. Enforce standard operation procedures upon vaccination centers without respect to their local conditions |
10. Create ways for vaccination centers to communicate and/or visit each other to learn from each other and to avoid unnecessary mistakes | 10. Stick to existing hierarchy structures to control everything–even if that causes delays |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Schulze, C.; Welker, A.; Kühn, A.; Schwertz, R.; Otto, B.; Moraldo, L.; Dentz, U.; Arends, A.; Welk, E.; Wendorff, J.-J.; et al. Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic. Vaccines 2021, 9, 887. https://doi.org/10.3390/vaccines9080887
Schulze C, Welker A, Kühn A, Schwertz R, Otto B, Moraldo L, Dentz U, Arends A, Welk E, Wendorff J-J, et al. Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic. Vaccines. 2021; 9(8):887. https://doi.org/10.3390/vaccines9080887
Chicago/Turabian StyleSchulze, Christoph, Andreas Welker, Anne Kühn, Rainer Schwertz, Benjamin Otto, Laura Moraldo, Udo Dentz, Albertus Arends, Eckhard Welk, Jean-Jacques Wendorff, and et al. 2021. "Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic" Vaccines 9, no. 8: 887. https://doi.org/10.3390/vaccines9080887
APA StyleSchulze, C., Welker, A., Kühn, A., Schwertz, R., Otto, B., Moraldo, L., Dentz, U., Arends, A., Welk, E., Wendorff, J. -J., Koller, H., Kuss, D., & Ries, M. (2021). Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic. Vaccines, 9(8), 887. https://doi.org/10.3390/vaccines9080887